Advanced melanoma has undergone a therapeutic revolution over the course of the past two decades, driven by immune checkpoint inhibitors (ICI), targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1), as well as BRAF-/MEK- targeted therapies. This evidence concerns the gene PDCD1 and melanoma.